Device Trial Radar · NCT01039467
A Comparison of the Pacemaker Automatic Features in Reduction of Ventricular Pacing
Last checked: Nov 20, 2026Latest source record: Feb 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
385
Actual
Start
Jun 2009
Primary completion
Apr 2014
Study completion Apr 2014
Sponsor
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart FailurePublic (MDT)
- Sponsor type
- Industry
- First posted
- Dec 25, 2009
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The COMPARE-Adapta study is a randomized, multi-center, prospective study conducted in China. The purpose of the study is to compare the ability of Search AV™+ and Managed Ventricular Pacing® (MVP®) to reduce ventricular pacing in dual chamber pacemaker-indicated patients. The COMPARE-Adapta study will also observe atrial fibrillation (AF) burden as demonstrated by Cardiac Compass® and the clinical profile Adapta® pacemaker patients.
Conditions
- Bradycardia
Interventions
Medtronic Adapta Dual Chamber PacemakerDevice
Medtronic Adapta Dual Chamber Pacemaker
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Decreased Percent of Ventricular Pacing Compared to MVP Using Search AV+Time frame: 1 month post-implantation
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Shanghai First People's Hospital
Shanghai, China
3rd Hospital of Beijing University
Beijing, Beijing Municipality, China
Anzhen Hospital
Beijing, Beijing Municipality, China
27 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.